New antibiotic shows promise for treating MRSA pneumonia

September 11, 2013



DETROIT - A drug approved just two years ago for treating bacterial infections may hold promise for treating the potentially fatal MRSA pneumonia, according to a Henry Ford Hospital study.

Researchers found that patients treated with the antibiotic ceftaroline fosamil, or CPT-F, had a lower mortality rate after 28 days than the mortality rate seen in patients treated with vancomycin, the most common drug therapy for MRSA pneumonia.

In the retrospective study, 33 of 38 patients responded well to treatments of CPT-F and were discharged from the hospital after the infection cleared. Of the five patients who died, three were attributed to other serious medical conditions.

The mortality rate for patients treated with vancomycin has been reported to be as high as 32 percent after 28 days. In the Henry Ford study, the mortality rate for the CPT-F treated population was 13 percent.

The study is being presented Wednesday at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Denver.

"Many things fall under the umbrella of proper and appropriate MRSA pneumonia treatment, and these results present a possible benefit with the use of CPT-F," says Samia Arshad, a Henry Ford Infectious Diseases epidemiologist and the study's lead author. "It is critical for us to find alternative drug therapies to improve patient outcomes. Further research is needed to test the efficacy of CPT-F on a larger patient population as CPT-F offers doctors another viable option for treating patients with MRSA pneumonia."

In 2010 the U.S. Food and Drug Administration approved CPT-F, an injectable antibiotic, for treating patients with bacterial infections like community-acquired bacterial pneumonia and skin infections. Henry Ford's study is the first to evaluate the efficacy of MRSA pneumonia patients treated with CPT-F. MRSA pneumonia is highly antibiotic resistant and most common in patients 65 years or older.

Researchers evaluated 38 patients treated with CPT-F. Twenty of these patients were failing standard treatment with either vancomycin and/or cefepime, and were switched to CPT-F. Researchers say no complications were reported in those 20 patients.

Researchers will continue to look for other patients treated with CPT-F for MRSA pneumonia, and will match these patients to others treated with different antibiotics to conduct a matched cohort analysis.
-end-
The study was funded by Forest Laboratories, Inc.

Henry Ford Health System

Related Mortality Rate Articles from Brightsurf:

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

Viral load predicts mortality rate in hospitalized patients with cancer and COVID-19
Higher viral loads are associated with a greater risk of death among cancer and non-cancer patients hospitalized with coronavirus disease 2019 (COVID-19), researchers report September 15 in the journal Cancer Cell.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

Study finds cancer mortality rate disparity based on hospital ratings
A new paper in the JNCI Cancer Spectrum, published by Oxford University Press, finds that the mortality rates for complex cancer procedures differ greatly between one-star hospitals (10.4%) and five-star hospitals (6.4%).

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

Mortality rate is cut in half by a lung rescue team at Massachusetts General
A specialized Lung Rescue Team established to evaluate and treat patients with obesity receiving mechanical ventilation due to acute respiratory failure has significantly reduced the risk of mortality

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Mortality rate 'weekend effect' not a reliable measure of care quality in hospitals
The higher mortality rate for weekend hospital admissions should not be used as an indicator of quality of care due to the lack of data preceding patient admission and on the severity of their illness, a new study conducted at the University of Warwick Medical School has concluded.

Read More: Mortality Rate News and Mortality Rate Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.